Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ledipasvir/Sofosbuvir for Hepatitis C in HCT Candidates
NCT03279133Phase 4Withdrawn
- Sponsor
- Kaiser Permanente
- Start
- Sep 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ledipasvir in hepatitis C (HCV), sponsored by Kaiser Permanente. Primary endpoint: Safety and Tolerability of LDV/SOF Treatment at 2 years. Planned start Sep 2017; status: withdrawn.
02
Drugs
ledipasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03279133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03279133.